Results 61 to 70 of about 1,361 (136)

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. [PDF]

EMBO Mol Med
Buzo K, Bizzozero L, Lentini M, Opattova A, Hernández-Suárez B, Torres M, Chiabotto G, Nisticò C, De Lazzari G, R Zanella E, Grasso G, Mariella E, Durinikova E, Linnebacher M, Sartore-Bianchi A, Siena S, Trusolino L, Bardelli A, Arena S.   +18 more
europepmc   +1 more source

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. [PDF]

Front Oncol
Karam MN, Hajj J, Crane CH, Ramia P, Geara F, Hamadeh N, Scott JG, Grobmyer S, Almond R, O'Reilly EM, Hajj C.   +10 more
europepmc   +1 more source

Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. [PDF]

iScience
Kolodziejczak AS, Selt F, Peterziel H, Jamaladdin N, Mack N, Maaß K, Meulenbroeks C, Sigaud R, Herold-Mende C, El Damaty A, Burhenne J, Ohmura S, Holland-Letz T, Kutscher LM, Ernst A, Wei PC, Grünewald TGP, Oehme I, Kool M, Jones DTW, Pajtler KW, Kratz CP, Pfister SM, Witt O, Milde T.   +24 more
europepmc   +1 more source

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. [PDF]

Ann Med
Ying T, E S, Ying H.
europepmc   +1 more source

PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. [PDF]

Cell Death Dis
Xi Q, Kunita A, Ogawa M, Kawakami M, Ka M, Nagai S, Duong AQ, Taguchi A, Watanabe K, Fukuda T, Sone K, Shinozaki-Ushiku A, Ushiku T, Hirota Y, Kage H, Katayama K, Oda K.   +16 more
europepmc   +1 more source

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer. [PDF]

Target Oncol
Johnson ML, Dakhil SR, Beck JT, Sadiq A, Menon S, Mugundu GM, Chmielecki J, Spigel DR.   +7 more
europepmc   +1 more source

Efficacy of Wee1 G2 Checkpoint Kinase and Mouse Double Minute 2 Homolog Inhibitors in Gastrointestinal Stromal Tumors Determined by p53 Status. [PDF]

Oncol Res
Chen CP, Tang YJ, Cai YY, Pan YR, Yeh CN, Huang WK, Lo CH, Hsiao YT, Shih HJ, Wu CE.   +9 more
europepmc   +1 more source

Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas. [PDF]

Blood Adv
Schmidt N, Kornrumpf K, Ries L, Markus K, Ksionsko NAM, Mazzeo P, Lohrberg M, Sitte M, Salinas G, Braun T, Dechow A, Herling M, Ianevski A, Aittokallio T, Chapuy B, Bastians H, Wulf G, Beißbarth T, Dönitz J, Koch R.   +19 more
europepmc   +1 more source

LncRNA Wee1-AS coordinates oxidative fatty acid metabolism through the activation of mitochondrial CDK1/CYCLIN B1. [PDF]

Signal Transduct Target Ther
Kim HJ, Jeong C, Lee SH, An S, Hyun GH, Lim GY, Kim JY, Lee J, Park MJ, Kwon SW, Kim W, Noh M, Han YH, Lee MO.   +13 more
europepmc   +1 more source

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRAS^G12C-mutant lung cancer. [PDF]

Cell Death Dis
Zhou C, Liu Y, Liu H, Lu J, Zhang B, Zhu L, Wang S, Lei H, Han B.   +8 more
europepmc   +1 more source